Article
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.
Nature communications - 12 Jun 2018
Russo Mariangela, Lamba Simona, Lorenzato Annalisa, Sogari Alberto, Corti Giorgio, Rospo Giuseppe, Mussolin Benedetta, Montone Monica, Lazzari Luca, Arena Sabrina, Oddo Daniele, Linnebacher Michael, Sartore-Bianchi Andrea, Pietrantonio Filippo, Siena Salvatore, Di Nicolantonio Federica, Bardelli Alberto
Abstract excerpt
Attempts at eradicating metastatic cancers with targeted therapies are limited by the emergence of resistant subclones bearing heterogeneous (epi)genetic changes. We used colorectal cancer (CRC) to test the hypothesis that interfering with an ancestral oncogenic event shared by all the malignant cells (such as WNT pathway alterations) could override heterogeneous mechanisms of acquired drug resistance. Here, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.